THE SOCIETAL AND HUMANISTIC BURDEN OF SMALL CELL LUNG CANCER (SCLC)- A SYSTEMATIC REVIEW OF SOCIETAL IMPACT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) LITERATURE
Author(s)
Enstone A1, Panter C1, Greaney MH1, Bennett B1, Penrod JR2, Yuan Y2
1Adelphi Values Ltd, Bollington, UK, 2Bristol-Myers Squibb, Princeton, NJ, USA
OBJECTIVES: SCLC, the most aggressive form of lung carcinomas, represents approximately 15% of all lung cancers. However, the societal and humanistic burden of SCLC is not well defined. The objective of this study was to explore the impact of SCLC through two systematic literature reviews (SLRs) on societal costs (SLR1) and HRQoL (SLR2). METHODS: Using the OVID search engine, SLRs were conducted in PubMed, MEDLINE® In‑Process, and Embase (SLR1 and SLR2); EconLIT and NHS EED (SLR1); and PsycINFO (SLR2). Searches were limited to human studies published between January 2005 and March 2016. Additional grey literature searches were conducted. In total, 591 abstracts were retrieved and systematically screened for eligibility, with 56 publications retained (29 SLR1 and 27 SLR2). RESULTS: The majority of publications provided data on limited and extensive stages of SCLC. Societal burden was reported as indirect and direct costs, with limited and heterogeneous data. The only reported indirect cost, lost productivity, was high in SCLC. SCLC was associated with high direct costs, specifically for chemotherapy, prophylactic therapies, and hospitalisation. Overall, HRQoL was reduced in patients with SCLC when compared with normative reference values. Specific HRQoL domains most commonly reported included activities of daily living (ADL) and physical, emotional, and cognitive functioning. ADL was the most severely impacted whereas cognitive functioning was the least. Possible differences in response to or tolerability of therapy existed, whereby not all therapies improved or maintained HRQoL. CONCLUSIONS: SCLC and its treatment have a substantial impact on societal costs, overall HRQoL, and some HRQoL domains. F
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCN219
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now